Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma.
作者信息
Augustin Ryan C, Luke Jason J
机构信息
UPMC Hillman Cancer Center, Pittsburgh, PA.
Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
出版信息
J Clin Oncol. 2023 Jan 20;41(3):443-446. doi: 10.1200/JCO.22.01770. Epub 2022 Sep 26.
Abstract
摘要
相似文献
1
Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma.伊匹木单抗的诱导暴露剂量与黑色素瘤辅助纳武单抗加伊匹木单抗治疗失败
J Clin Oncol. 2023 Jan 20;41(3):443-446. doi: 10.1200/JCO.22.01770. Epub 2022 Sep 26.
2
Real-world efficacy of nivolumab plus ipilimumab combination therapy versus nivolumab monotherapy for Stage IV melanoma patients in Asia.纳武利尤单抗联合伊匹木单抗与纳武利尤单抗单药治疗对亚洲IV期黑色素瘤患者的真实世界疗效
Eur J Dermatol. 2021 Oct 1;31(5):662-664. doi: 10.1684/ejd.2021.4139.
3
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药治疗与安慰剂用于无疾病证据的 IV 期黑色素瘤患者（IMMUNED）：一项随机、双盲、安慰剂对照、II 期试验。
Lancet. 2020 May 16;395(10236):1558-1568. doi: 10.1016/S0140-6736(20)30417-7.
4
Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.一名转移性恶性黑色素瘤患者在使用纳武单抗治疗失败后，因使用伊匹单抗诱发大疱性类天疱疮。
J Dermatol. 2018 Jan;45(1):e21-e22. doi: 10.1111/1346-8138.14043. Epub 2017 Sep 25.
5
Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.一名黑色素瘤患者在接受纳武单抗治疗后使用伊匹单抗治疗时发生1型糖尿病。
J Dermatol. 2018 Oct;45(10):e289-e290. doi: 10.1111/1346-8138.14331. Epub 2018 Apr 18.
6
Tumor lysis syndrome associated with nivolumab plus ipilimumab combination therapy in a melanoma patient.一名黑色素瘤患者中与纳武单抗加伊匹单抗联合治疗相关的肿瘤溶解综合征
J Dermatol. 2020 Nov;47(11):e411-e412. doi: 10.1111/1346-8138.15547. Epub 2020 Aug 27.
7
Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity.辅助纳武利尤单抗联合伊匹单抗治疗期间隐匿性检查点抑制剂心肌炎：一种潜伏但严重的毒性。
Immunotherapy. 2024;16(14-15):937-942. doi: 10.1080/1750743X.2024.2385286. Epub 2024 Sep 11.
8
Acrocyanosis after neoadjuvant ipilimumab plus nivolumab: a case report.
Clin Exp Rheumatol. 2020 Sep-Oct;38(5):1031-1032. Epub 2020 Apr 17.
9
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的 5 年生存数据
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
10
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药对比伊匹单抗单药治疗晚期黑色素瘤（CheckMate 067）：一项多中心、随机、III 期临床试验的 4 年结果。
Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22.
引用本文的文献
1
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma.黑色素瘤的术前和术后系统治疗的快速发展。
Am J Clin Dermatol. 2024 May;25(3):421-434. doi: 10.1007/s40257-024-00852-5. Epub 2024 Feb 26.
本文引用的文献
1
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).纳武利尤单抗联合伊匹木单抗辅助治疗与纳武利尤单抗单药治疗 IIIB-D 期或 IV 期黑色素瘤患者的比较（CheckMate 915）
J Clin Oncol. 2023 Jan 20;41(3):517-527. doi: 10.1200/JCO.22.00533. Epub 2022 Sep 26.
2
Optimal systemic therapy for high-risk resectable melanoma.高危可切除黑色素瘤的最佳全身治疗。
Nat Rev Clin Oncol. 2022 Jul;19(7):431-439. doi: 10.1038/s41571-022-00630-4. Epub 2022 Apr 25.
3
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).基于早期、中期影像学评估的晚期黑色素瘤患者纳武利尤单抗+伊匹单抗免疫治疗的适应性剂量调整（ADAPT-IT 研究）。
J Clin Oncol. 2022 Apr 1;40(10):1059-1067. doi: 10.1200/JCO.21.01570. Epub 2021 Dec 20.
4
Ipilimumab Combination Dosing: Less is More.依匹木单抗联合用药剂量：少即是多。
Clin Cancer Res. 2021 Oct 1;27(19):5153-5155. doi: 10.1158/1078-0432.CCR-21-2406.
5
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.帕博利珠单抗联合伊匹木单抗治疗抗 PD-1/PD-L1 失败的黑色素瘤。
J Clin Oncol. 2021 Aug 20;39(24):2647-2655. doi: 10.1200/JCO.21.00079. Epub 2021 May 4.
6
Targeted agents and immunotherapies: optimizing outcomes in melanoma.靶向药物和免疫疗法：优化黑色素瘤的治疗效果。
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482. doi: 10.1038/nrclinonc.2017.43. Epub 2017 Apr 4.
7
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.纳武利尤单抗联合伊匹木单抗作为晚期非小细胞肺癌的一线治疗方案（CheckMate 012）：一项开放标签的1期多队列研究结果
Lancet Oncol. 2017 Jan;18(1):31-41. doi: 10.1016/S1470-2045(16)30624-6. Epub 2016 Dec 5.
Zotero 插件